France · Delayed Price · Currency is EUR Sartorius Stedim Biotech Earnings Call Transcripts
Fiscal Year 2026
-
Sales grew 7.5% in constant currencies in Q1 2026, with strong recurring business and resilient profitability. Full-year guidance is confirmed, expecting 5%-9% sales growth and EBITDA margin above 30%, while deleveraging and disciplined investment continue.
-
The meeting confirmed strong 2025 financial growth, approved all resolutions, and outlined strategic priorities in innovation, operational efficiency, and sustainability. Dividend of €0.71 per share was proposed, and auditors issued unqualified opinions. All agenda items passed with high shareholder participation.
-
Ambitious midterm targets include 8%-11% organic revenue growth and margin expansion, driven by innovation in single-use technologies, AI, and advanced therapies. Regional growth is led by the U.S. and Asia, with operational excellence and customer experience as key priorities.
Fiscal Year 2025
-
Delivered strong 2025 results with 7.6% constant currency sales growth and EBITDA margin of 29.7%, driven by recurring business and operational leverage. 2026 guidance anticipates 5%-9% sales growth and margin above 30%, with continued investment in innovation and global capacity.
-
Sales grew 7.5% in constant currencies to €2.6B, driven by strong consumables demand and margin expansion to 29.7%. BPS delivered double-digit growth, while LPS improved gradually. Full-year guidance was raised, with continued deleveraging and robust innovation pipeline.
-
H1 2025 delivered 6% revenue growth and 12% EBITDA growth, led by strong consumables demand and margin expansion. BPS outperformed with 9% sales growth, while LPS remained challenged. Full-year guidance is confirmed, with higher confidence in BPS amid ongoing market uncertainties.
-
Q1 2025 saw strong growth in consumables and recurring revenue, driving margin expansion and robust cash flow, while equipment sales remained soft. Guidance for 2025 anticipates 6% sales growth and a 29%-30% EBITDA margin, with tariff impacts being actively managed.
-
The meeting covered board renewals, strong 2024 financials, and major global expansions. All resolutions, including dividend, board appointments, and sustainability initiatives, were approved. Key risks discussed included geopolitical uncertainties and market normalization.
Fiscal Year 2024
-
2024 results met revised guidance with flat sales and robust margins, driven by consumables growth and efficiency gains. Free cash flow doubled, leverage improved, and 2025 is expected to bring moderate, profitable growth above market rates, with continued focus on deleveraging.
-
Nine-month 2024 results met expectations, with robust recurring business and strong order intake offsetting weak equipment sales. Profitability and cash flow improved, guidance for the year is confirmed, and efficiency programs are set to deliver significant savings in Q4.
-
H1 results met sales and margin targets, but demand remains muted amid ongoing market volatility and post-pandemic normalization. Full-year guidance was de-risked to flat sales with a 27%-29% EBITDA margin, while efficiency programs and lower CapEx support financial stability.